In Exp. 1, 45 fine-wool ewes received (sc) either 0, 50 or 100 mg epostane (3-3-hydroxysteroid dehydrogenase inhibitor) to examine effects on return to estrus and conception rates. Treatments were imposed on d 10 of an estrous cycle (estrus = d 0) and jugular blood samples were collected once daily on d 8 and 9, twice daily on d 10 through 13 and once daily from d 14 until first post-treatment estrus or d 20 (15 ewes/treatment). Intensive samples were obtained hourly for 6 h after treatment (d 10; five ewes/treatment). Serum progesterone (P4) before treatment was similar among groups; but by 2 h after treatment, epostane-treated ewes had lower (P<.IO) values than controls. By 6 h post-treatment, serum P4 in ewes receiving 50 (1.0 ng/ml) and 100 (.9 ng/ml) mg epostane was well below control values (3.2 ng/ml). By 7 d after treatment, 93.3% of ewes treated with 50 mg epostane had recycled compared with 66.7 and 33.3% of those receiving 100 and 0 rag, respectively (P<.10). Similarly, 93.3, 53.3 and 26.7% of ewes receiving 50, 100 or 0 mg epostane, respectively, lambed to breeding within 7 d of treatment (P<.05). Overall conception rates during a 34-d breeding season were similar among groups. Preweaning performance of offspring did not differ among maternal treatments. A single injection of epostane lowered serum P4, but P4 levels were not maintained low enough and(or) long enough to allow ewes to return to estrus immediately after treatment. Experiment 2 attempted to determine if two 50-rag epostane injections could successfully hasten onset of estrus and(or) influence follicular growth. Ten fine-wool ewes received two injections at 12-h intervals containing either 0 or 50 mg epostane. Treatments were administered on d 10 (1800) and 11 (0600) of an estrous cycle. Blood samples were collected twice daily (0600 and 1800) from d 10 to onset of estrus or d 20. Intensive samples were obtained before and after second treatment (d 11, 0600) at 30-min intervals for 4 h and hourly for 8 h. Mid-ventral laparotomies were performed on all ewes on d 13. Serum P4 was similar before treatment among groups, but by 12 h after first injection, P4 was lower (P<.01) in ewes treated with epostane. A second epostane injection did not further reduce P4 at 2, 6 or 12 h after treatment. Progesterone remained lower (P<.05) in treated ewes for 84 h after first treatment. Epostane did not alter number of corpora lutea or follicles and did not reduce the interval from treatment to onset of estrus compared with that observed in controls. Reduction of serum P4 induced by epostane administration does not appear to allow early return to estrus or enhance follicular growth in cycling ewes.
Introduction
Reproductive physiologists have strived for many years to develop techniques to control onset of estrus and ovulation in domestic animals. Estrous synchronization has been a valuable tool in regulating the estrous cycle and ovulation in a variety of species. Early studies showed that progesterone and(or) progestogens administered by injection (Dutt and Casida, 1948; Cullen and Shearer, 1964) , intravaginal sponge Gorden and Maher, 1971) or orally (Evans et al., 1962; 1072 J. Anim. Sci. 1986 .63:1072--1077 Lindsay et al., 1967) could be effective in synchronization. However, progestogen administration was shown to reduce fertility at first post-treatment estrus (Curl et al., 1967; Ruttle and Menzies, 1975) . Prostaglandins lead to corpus luteum (CL) regression, thereby inducing estrus (Inskeep, 1973; Hafs et al., 1974) . However, prostaglandin F2a may reduce conception in sheep (Boland et al., 1978; Bredee-Ortiz, 1984) . Another potential method for estrous manipulation might be to block progesterone synthesis by inhibiting the 3-/3 hydroxysteroid dehydrogenase (HSD) enzyme. Trilostane, a 3-/3 HSD inhibitor was shown to have potential in inducing parturition in sheep (Taylor et al., 1982) . To date, however, no data are available in which these enzyme inhibitors have been evaluated as to their effect on physiological events controlling the estrous cycle. These studies were designed to examine effects of epostane, a specific 3-/3 HSD inhibitor, on the estrous cycle, ovarian characteristics, progesterone levels and preweaning performance of offspring in cycling, fine-wool sheep.
Materials and Methods
Exp. 1. Data were obtained from 45 multiparous fine-wool ewes of similar breeding that were maintained in one pen (14.3 • 18.3 m) and managed as a single group. Vasectomized rams were joined with females (1 mo before treatment) and estrous observations were made twice daily. After ewes exhibited one normal estrous cycle (14 to 20 d), they were randomly allotted to one of the three treatment groups (15 ewes/group). On d 10 of the next estrous cycle (day 0 = estrus), animals were given a single injection (sc) of either 0 (carrier vehicle), 50 or 100 mg epostane 3. On the day of treatment, all ewes were transferred to a second pen (14.3 • 18.3 m) containing fertile Debouillet rams fitted with marking harnesses at which time estrous observations were made twice daily for 34 d after treatment.
Daily blood samples (0600) were collected by jugular venipuncture on d 8 and 9 of the treatment cycle. Blood samples were collected twice daily (0600 and 1800) from d 10 through a 3-/3 HSD inhibitor, Sterling Winthrop Res. Inst., Rensselear, NY. d 13, while one sample was collected daily (0600) from d 14 until post-treatment estrus or d 20 of the cycle. In addition, five ewes from each treatment group (15 ewes total) were randomly chosen for intensive sampling. On the day of treatment (d 10), a blood sample was obtained before treatment (0600), after which hourly samples were collected for 6 h. Serum was separated by centrifugation (2,300 x g at 4 C) and stored at -20 C. Serum progesterone (P4) was quantified using a radioimmunoassay (RIA) described by Hallford et al. (1982) . Specificity of the antiserum was determined by Gibori et al. (1977) .
Ewes were allowed free access to shelter, water, salt and minerals. All ewes were fed the same pelleted diet, which was offered at 1.6 kg-head -1 "d -1 during the first 14 wk of gestation and 1.6 kg plus .45 kg milo-heaa rl'd -1 during the last 6 wk of gestation. Following parturition, ewes were given 2.7 kg'head -1 "d -1 of the pelleted diet until all lambs were weaned. Dietary ingredients were primarily cottonseed hulls (45.5%), milo (25.3%), alfalfa (20.5%), molasses (5%) and cottonseed meal (3.5%). The diet contained the following average composition (dry matter basis): 91.6% dry matter (DM), 11.5% crude protein (CP), 2.0% ether extract (EE) and 39.8% acid detergent fiber (ADF). Ewes were weighed before the trial began and at monthly intervals throughout gestation and lactation. After parturition, lamb birth weights, sex and type of birth were recorded. Lambs were weaned at 60 d of age and weaning weights were adjusted to a mature ewe, single-ewe-lamb basis (Scott, 1977) .
Exp. 2.
Ten mature fine-wool ewes were randomly allotted to one of two treatment groups (five ewes/group). Vasectomized rams were joined with females and estrous observations were made twice daily. After one normal estrous cycle, ewes received either 0 or 50 mg epostane (sc) on d 10 (1800) of the next estrous cycle. On the day of treatment, ewes were then transferred to a second pen containing fertile Debouillet rams fitted with marking harnesses, and were treated in the same manner as described in Exp. 1. Twelve hours (d 11, 0600) after the initial injection, ewes received a second injection of 0 or 50 mg epostane. Blood samples were collected twice daily (0600 and 1800) by jugular venipuncture, beginning on d 10 until return to estrus or d 20. In addition, acute effects of epostane were determined from intensive samples before and after the second treatment on d 11. One sample was obtained before (0 min) the second injection and post-treatment samples were taken at 30-rain intervals for 4 h and hourly for 8 h. Serum was separated, stored and assayed in the same manner as described in Exp. 1. On d 13 following estrus (2 d after last treatment), mid-ventral laparotomies (Lamond and Urquhart, 1961) were performed on each ewe. Number and size of follicles and(or) CL and ovarian size were recorded. Ewes were allowed free access to shelter, water, salt and minerals. All ewes were fed a pelleted diet at 1.6 kg-head -1 9 d -1 during the first 14 wk of gestation and 1.6 kg plus .3 kg corn.head -1.d -1 during the last 6 wk of gestation. Following parturition, ewes were fed 2.7 kg-head -1 -d -1 of the pelleted diet until lambs were weaned. Dietary ingredients were: alfalfa meal (96.4%), molasses (3%) and monosodium phosphate, 26% P (.5%). The diet contained the following average composition (dry matter basis): 90.9% DM, 17.5% CP, 3.7% EE and 31.3% ADF. After parturition lambs were managed as described in Exp. 1.
Statistical Analysis. Categorical data (lamb-
ing data and reproductive responses)were analyzed using a chi square procedure reported by Grizzle et al. (1969) . Progesterone values were subjected to split-plot analysis of variance for repeated measures on animals as described by Gill and Hafs (1971) . Analyses of variance were employed to examine animal weights and ovarian characteristics using completely random designs (Snedecor and Cochran, 1967) . When treatment effects were detected, means were separated using the least significant difference method. Mean differences with a probability greater than .10 were considered to be not different.
Results and Discussion
Exp. i. Ewe weights obtained during the month in which treatments were imposed did not differ among the three treatment groups. Weights were also similar 1, 2 and 3 mo after administration of epostane. Four months after treatment, control ewes weighed (mean -+ SE) 79.2 -+ 2.5 kg compared with 81.1 -+ 2.5 and 84.0 -2.5 kg for those receiving 50 and 100 mg epostane, respectively. These data demonstrate that epostane did not adversely influence animal weight responses compared with those observed for control ewes.
Serum P4 values were similar among treatment groups 1 h after treatment (figure 1). However, P4 declined (P<.01) dramatically by 2 h after treatment in ewes receiving 50 or 100 mg epostane compared with control ewes. Progesterone levels continued to decrease in ewes treated with epostane and by 12 h after treatment, P4 levels were approximately fourfold lower (P<.01) in ewes receiving 50 or 100 of epostane than in controls. Serum P4 remained at approximately 2.0 ng/ml from 36 to 72 h after treatment with epostane; and by 84 h post-treatment, ewes receiving 50 mg epostane had P4 values that did not differ from control values. Although P4 differed (P<.01) in ewes receiving 50 (2.0 + .3 ng/ml) or 100 (1.9 + .3 ng/ml) mg epostane compared with controls (3.6 + .3 ng/ml) 36 h after treatment, the ovary seemed to have essentially overcome the epostane inhibition since P4 levels at this time approached the near normal mid-luteal levels reported by Hallford et al. (1982) . Similar P4 responses to epostane treatment were observed in pregnant ewes by Taylor et al. (1982) . Within 6 d after treatment, 40% of ewes receiving 50 mg of epostane returned to estrus, compared with none of the controls and 13.3% of ewes receiving 100 mg of epostane (P<.05; table 1). By 7 d after treatment, 93.3% of the e'f'gRow values that do not have a common superscript differ (P<.10).
50-mg group had cycled. However, by 10 d after treatment, no differences were noted among treatments with all ewes returning to estrus in the 0-and 50-rag groups, and 80% in the 100-mg group. These data demonstrate that 50 mg epostane may indeed cause ewes to cycle about 1 d earlier than controls; however, 100 mg appears to affect adversely return to estrus since three ewes in this group failed to cycle within 10 d after treatment. All ewes receiving 50 mg epostane, 80% of the controls and 53.3% of those receiving 100 mg epostane conceived to mating within 8 d after treatment (table 1) . Therefore, 50 mg epostane does not adversely affect time intervals from treatment to conception.
Two control ewes and one ewe receiving 100 mg epostane failed to conceive during the 34-d breeding season following treatment while all ewes receiving 50 mg epostane conceived during this period. Neither total nor live lambs born/ ewe mated differed in control ewes (1.4 and 1.4, respectively) and those receiving 50 (1.7 and 1.6, respectively) or 100 (1.5 and 1.1, respectively) mg epostane. Treatment with 50 or 100 mg epostane had no adverse effects on conception rate or lambs born.
Preweaning growth response of offspring produced by experimental ewes was also examined. Lambs were not creep-fed during the preweaning period, but they had free access to the ewe diet. Neither birth weight, actual weaning weight, 60-d adjusted weight nor preweaning gain/day differed among treatments. Maternal epostane treatment, therefore, does not hamper preweaning growth performance of offspring.
Exp. 2. Data obtained from Exp. 1 indicated that a single injection of epostane lowered serum P4, but P4 levels were not mainained low enough and(or) long enough to allow ewes to return to estrus immediately after treatment. Experiment 2, therefore, attempted to determine if two 50-mg epostane injections administered at 12-h intervals could successfully hasten onset of estrus. If P4 were lowered during the mid-luteal phase of the estrous cycle to a level not low enough to allow expression of estrus but sufficient to encourage gonadotropin production, one might expect follicular growth to be enhanced. Thus a second objective of Exp. 2 was to evaluate via laparotomy the influence of two 50-mg epostane injections on ovarian characteristics of fine-wool ewes.
Serum P4 values in samples collected 12 h before and for 108 h after first injection are presented in figure 2. Progesterone did not differ among treatments before epostane was administered. These values are similar to those reported by Hudgens and Hallford (1983) during the luteal phase of the estrous cycle, indicating a functional CL in all ewes. Twelve hours following the first injection, P4 was approximately threefold lower in ewes receiving 50 mg of epostane than in controls (P<.01). This decline in P4 is similar to that observed in Exp. 1. Intensive samples obtained after a second injection indicated that P4 remained lower (P<.05) in ewes receiving 50 mg epostane compared with controls. However, values were no lower 12 h following second injection than 12 h following first injection. These data demonstrate that 50 mg epostane will rapidly reduce P4 levels in cycling ewes, but an additional 50 mg of epostane 12 h after the first treatment does not further decrease serum P4. Ewes treated with epostane continued to have lower (P<.05) concentrations of P4 than did control ewes up to 84 h after first injection. However, by 108 h after initial treatment, P4 levels in epostane-treated ewes were similar to control values (figure 2).
Mid-ventral laparotomies were performed on day 13 (48 h after second treatment). Number of CL did not differ between control and treated ewes ( bTreatments (sc) were administered at 1800 on d 10 and 0600 on d 11 of an estrous cycle (estrus=d 0).
CData are means expressed on a per ewe basis. Laparotomies were performed on d 13 (48 h after final treatment 9 dn = seven and eight for control and epostane, respectively (one lamb weight was not obtained).
50-mg injections of epostane. Likewise, 80% of ewes in each treatment group conceived during the first post-treatment estrus, and all ewes conceived during the 34-d breeding season following the second injection. Treated ewes produced the same number of lambs (1.6 lambs/ewe) as control ewes, which further supports laparotomy data, indicating that epostane did not influence follicular development. No differences were noted in lamb birth weight when offspring of control ewes were compared with those from treated ewes.
Results obtained from these experiments demonstrate that 50 mg epostane decreased serum P4; however, a second injection of epostane 12 h after the first did not further reduce the level of P4. This reduced P4 did not lead to a dramatic shortening of the estrous cycle. Likewise, reducing serum P4 for approximately 72 h during the mid-luteal phase of the cycle did not allow enhanced follicular growth. Epostane, therefore, does not appear promising as an estrous synchronizing agent in sheep.
